KITE 753 Trials Placed on Partial Clinical Hold

Company Kite (Gilead) Event Type Partial clinical hold (earnings call) Modality Autologous bicistronic CD19/CD20 CAR-T Asset KITE-753 (PALISADES-1, PALISADES-2) Target CD19; CD20 Disease Area Relapsed or refractory diffuse large B-cell lymphoma Summary Gilead disclosed on its 29 October earnings call that PALISADES-1 and PALISADES-2, studying…